In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer: a single centre phase II study.

Trial Profile

In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer: a single centre phase II study.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REMOTUX
  • Most Recent Events

    • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-013279-23).
    • 11 Sep 2009 New trial record
    • 04 Sep 2009 Status changed to completed as per ISRCTN record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top